Reference Drug Program (RDP) Review Reports

In modernizing the Reference Drug Program (RDP), the Ministry of Health reviewed the available research, clinical evidence, and coverage recommendations for the classes of drugs covered under the RDP.

A selection of these materials, including the Drug Benefit Council recommendation, is available below.

The Ministry of Health and Drug Benefit Council reviewed an extensive library of materials relating to all drug classes covered under the RDP. Many of these materials and studies include proprietary or protected information, or are otherwise not readily available. The list below includes only those materials that are freely available to the public.

NAME OF DOCUMENT DESCRIPTION
Drug Benefit Council Recommendation: Reference Drug Program (PDF)
September 14, 2014
In September 2014, the Drug Benefit Council (DBC) reviewed the RDP, including the proposed and existing drug classes. This report is the DBC’s recommendation for the modernization of the RDP.
Histamine2 Receptor Antagonist Review This review, based on published studies of clinical trials, reports on available H2 Blockers and their efficacy and use in patients with gastric and duodenal ulcers, as well as gastroesophageal reflux disease. The review was prepared in 2010 by Provider Synergies LLC.
Proton Pump Inhibitor (PPI) Drug Class Review 
(Drug Effectiveness Review Project)
This Drug Class Review, prepared in 2009 by researchers affiliated with the Oregon Health and Science University and the Drug Effectiveness Review Project, compares the benefits and harms of PPIs for the treatment of gastroesophageal reflux disease, H. pylori infection, peptic ulcers, and non-steroidal anti-inflammatory drug-induced ulcers.
PPI Clinical Evidence Review (PDF) This comprehensive review of clinical evidence reports on the comparative efficacy and safety of PPIs in the treatment of gastroesophageal reflux disease and peptic ulcer disease. This 2014 report is an update of the 2009 PPI Drug Class Review conducted by the Drug Effectiveness Review Project (above).
PPI Optimal Therapy Report Prepared by the Canadian Optimal Medication Prescribing and Utilization Service (COMPUS) in 2007, this report is a comprehensive review of evidence based literature with recommendations on the optimal use and prescribing of PPIs in the treatment of gastroesophageal reflux disease, dyspepsia, and peptic ulcer disease.
Statins Drug Class Review 
(Drug Effectiveness Review Project)
This Drug Class Review, prepared in 2009 by researchers affiliated with the Oregon Health and Science University and the Drug Effectiveness Review Project, compares the efficacy and safety of statins and statin-combination products in adults and children.
Treatment of Non-Ulcer Dyspepsia in Adults: Common Questions about H2-blockers Written by the Therapeutics Initiative affiliated with the University of B.C., this 1994 article provides an overview of available H2 Blockers and addresses common questions regarding the treatment of dyspepsia with H2 blockers.